Englesbe MJ, Dubay DA, Wu AH, Pelletier SJ, Punch JD, Franz MG. Gallbladder Disease in Cardiac Transplant PatientsA Survey Study. Arch Surg. 2005;140(4):399-403. doi:10.1001/archsurg.140.4.399
Preemptive cholecystectomy in cardiac transplant patients with radiographic biliary pathology reduces the morbidity and mortality of biliary tract disease following heart transplantation compared with expectant management.
Design and Setting
Institutional survey at the University of Washington, Seattle.
Cardiac transplant recipients between January 1, 1992, and January 1, 2001.
Main Outcome Measure
Clinical course of patients who were diagnosed as having biliary tract disease following heart transplantation and were managed expectantly (observed) compared with the course of patients whose conditions were diagnosed and who underwent an operation.
Sixty (35.7%) of 168 cardiac transplant patients were evaluated for biliary tract pathologic condition. Of the 71.7% (43 of 60 patients) who had an abnormal radiographic evaluation, 46.5% (20 patients) had surgery on their biliary tract while the other patients were observed. Nine of the 23 patients who were followed up expectantly had cholelithiasis, 7 patients had gallbladder wall thickening, 5 patients had sludge in their gallbladder, and 2 had biliary dilatation. These patients were followed up for a mean ± SD of 3.7 ± 1.3 years; none developed biliary tract symptoms during this period. Cholecystectomies were completed for both emergent (7) and elective (14) indications. The mean ± SD length of stay for patients who had emergent operations was 24.3 ± 11.2 days, compared with 3.2 ± 2.8 days for the patients who had elective operations. Seven (33%) of the 21 patients who had an operation had a significant complication and 1 patient died.
These data suggest that the morbidity of an elective cholecystectomy in cardiac transplant patients is significant and equivalent to the morbidity associated with emergent procedures. Expectant management of patients with radiographic evidence of biliary tract pathology discovered after transplantation was safe in this series.
Heart transplantation is associated with an increased risk for the development of cholelithiasis.1 Population-based studies suggest that the incidence of pancreaticobiliary disease is up to 17 times greater in patients receiving heart transplantation compared with the general population.2 Several series report that 30% to 55% of patients screened after transplantation will develop cholelithiasis.3- 7 However, these studies likely overestimate the true incidence of posttransplant cholelithiasis owing to screening bias introduced by low incidence of posttransplantation biliary tract surveillance. Significant controversy exists regarding the need for comprehensive biliary tract screening after transplantation in asymptomatic patients. Unfortunately, there are limited and conflicting data in the surgical literature regarding optimal management of cardiac transplant patients with asymptomatic cholelithiasis. Treatment recommendations range from cholecystectomy only for symptomatic patients, to screening of all cardiac transplant patients for biliary tract pathology with preemptive cholecystectomy for those patients with cholelithiasis.3- 5,8- 10
The argument for comprehensive screening of all cardiac transplant patients for biliary tract pathology and immediate cholecystectomy for those patients with cholelithiasis is based on the following 3 observations: there is a high prevalence of biliary tract disease in the heart transplant population; many patients develop symptomatic biliary tract disease shortly after transplantation; and there is substantial morbidity and mortality associated with urgent biliary tract operations in this population. Using the framework of these 3 observations, the aim of this study was to specifically address whether preemptive cholecystectomy in the asymptomatic cardiac transplant patients reduces the morbidity and mortality of biliary tract disease following heart transplantation compared with expectant management.
Approval for this study was obtained through the University of Washington Institutional Human Subjects Committee, Seattle. Data were collected retrospectively and entered in “de-identified” research records. The medical records of all adults cardiac transplant recipients treated at the University of Washington Medical Center between January 1, 1992, and January 1, 2001, were reviewed to identify patients who were evaluated for biliary tract pathology. Data obtained included demographic information (gender and age at transplantation), baseline clinical information (type of disease leading to end-stage heart failure, medical comorbidities, ejection fraction, renal function, and liver function), data on general clinical course (immunosuppressive regimen, length of stay, and cause of death), and information specific to the biliary tract disease (method of diagnosis, age at time of diagnosis, imaging results, pathology reports, and operative reports). A positive imaging study was defined as cholelithiasis, choledocholithiasis, gallbladder wall thickening determined to be “significant” by an attending radiologist, sludge in the gallbladder, or biliary tract dilatation. Perioperative morbidity and mortality were limited to 30 days following a biliary operation. An emergent operation was defined as surgery within 24 hours of diagnosis or admission to the hospital. Atypical symptoms are defined as no abdominal pain, nausea, or vomiting.
Baseline characteristics were compared using the Fisher exact test for dichotomous variables and the Wilcoxon rank sum test for continuous variables. Statistical analysis was performed using SAS version 8.0 (SAS Institute, Cary, NC).
One hundred eighty-three patients underwent heart transplantation between January 1, 1992, and January 1, 2001. Fifteen patients had a cholecystectomy prior to heart transplantation and are excluded from all analyses. An imaging study of the biliary tract was done in 60 (35.7%) of the 168 posttransplantation patients. Forty-nine of these patients were referred for imaging owing to suspicion of biliary tract disease, while 11 had an imaging study for other indications and biliary tract findings were noted incidentally. An abnormal radiographic study was found in 43 (71.6%) of 60 posttransplantation patients who underwent imaging. Twenty-one (35%) of the 60 patients who underwent imaging had a biliary tract operation following transplantation.
The baseline characteristics of the 60 patients who had an evaluation of their biliary tract following their cardiac transplantation are listed in Table 1. There were no significant differences in the baseline characteristics between the groups with an abnormal and normal radiographic study.
The mean ± SD age at the time of diagnosis of biliary tract disease was 48.7 ± 21.1 years. The mean ± SD interval between transplantation and the first abnormal study was 619.1 ± 799.2 days. Nine of 43 posttransplantation patients had an initial ultrasonogram that was negative for cholelithiasis, but the patients later developed cholelithiasis. The mean ± SD interval between the normal and abnormal study was 903 ± 800.7 days. The clinical characteristics of the 60 patients who had an evaluation of their biliary tract are listed in Table 2. Patients with a negative study were more likely to have an elevated serum bilirubin level (58.8% vs 26.8%, P = .01). As expected, patients with an abnormal result were more likely to undergo an operation (46.5% vs 5.8%, P = .004). Immunosuppressive medications used included cyclosporine, tacrolimus, mycophenolate mofetil, azathioprine sodium, and corticosteroids. Immunosuppressive regimen was not associated with either a positive radiographic study or need for an operation.
Of the 43 patients who had an abnormal radiographic evaluation, 20 patients (46.5%) had surgery on their biliary tract while the other 23 were observed. The characteristics of patients who had surgery were compared with patients who did not have an intervention (Table 3). As expected, patients with abdominal pain were more likely to have an operation (43.5% vs 85.0%, P = .01). Nine of the 23 patients who were followed up expectantly had cholelithiasis, 7 patients had gallbladder wall thickening, 5 patients had sludge in their gallbladder, and 2 had biliary dilatation. These patients were followed up for a mean of 3.7 ± 1.3 years and none developed biliary tract symptoms during this period. Four of these 23 patients who were clinically followed up died. The causes of death include graft failure, renal cell cancer, fungal sepsis (pulmonary), and sepsis from a liver abscess. The patient with the liver abscess had diffuse gallbladder wall thickening along with heart failure and a patent biliary system by nuclear scan. The abscess contained Fusobacterium and was not thought to be associated with biliary tract pathology at autopsy.
Nineteen laparoscopic cholecystectomies were completed for both emergent (7/7) and elective (12/14) indications (Table 4). Two open cholecystectomies were also done. None of the 108 patients who did not have imaging of their biliary system required an operation. The mean length of stay for patients who had emergent operations was 24.3 ± 11.2 days compared with 3.2 ± 2.8 for the patients who had elective operations. Most of the patients who required emergent operations were admitted for other significant medical problems (ie, line sepsis, renal failure, or adult respiratory distress syndrome). The mean ± SD white blood cell count was significantly higher in patients who had an emergent operation (11.2 ± 6.9 vs 5.4 ± 2.4, P = .05). Emergent operations were not associated with more complications. Complications included biliary fistula, rupture of pancreatic pseudocyst, recurrent choledocholithiasis, bleeding (requiring transfusion), cerebrovascular accident, and acute renal failure. The biliary fistula and the bleeding occurred in 2 patients who had an open repair. The patient with the biliary fistula was cirrhotic and died from liver failure in the postoperative period.
Diabetic patients were significantly more likely to undergo an emergent procedure (71.4% [5/7]) rather than an elective operation (14.3% [2/14], P = .02). In addition, diabetic patients were more likely to present with abdominal pain (78.9% [15/19]) compared with nondiabetic patients (46.3% [19/41], P = .047).
This study confirms that cardiac transplant patients have a high prevalence of biliary tract disease. Radiographic evidence of biliary tract pathology (gallbladder wall thickening excluded) was found in 35 (20.8%) of 168 cardiac transplant patients. This is approximately twice the expected prevalence compared with North American groups of the same age, gender, and race.7 Posttransplant cholelithiasis developed relatively early in the postoperative period. The mean time from heart transplant to diagnosis of cholelithiasis was 1.69 ± 2.19 years. Several potential explanations for the increased prevalence of biliary tract disease in these patients include vagotomy with associated biliary stasis following transplantation, rapid weight loss following transplantation, obesity, atherosclerosis, and hemolysis.1 There also are reports that cyclosporine therapy increases bile lithogenicity.11 Our study did not establish any correlation between cholelithiasis and any specific immunosuppressant medication or regimen, although the small cohort of patients studied may limit the ability to detect any significant correlations.
Despite the high incidence of biliary tract pathology, there is no uniform consensus regarding the optimal management of cholelithiasis in cardiac transplant patients. Studies reported in the surgical literature seem to favor prophylactic cholecystectomy for patients identified with cholelithiasis preoperatively. Patients with asymptomatic cholelithiasis before transplantation commonly develop symptoms and often complications after transplantation. Two studies noted that biliary-associated symptoms developed within 2 years following heart transplantation in 58% and 45% of patients with documented asymptomatic gallstones before transplantation.10,12 There also are several reports of patients developing complicated biliary tract pathologic conditions in the immediate postoperative period associated with a high mortality rate.3 The other main argument favoring preoperative elective cholecystectomy is a significantly decreased perioperative morbidity compared with posttransplant elective or emergent cholecystectomy, despite the obvious impaired preoperative cardiac function.5
An equally controversial topic is the management of patients identified with asymptomatic cholelithiasis after heart transplantation. The main argument supporting prophylactic cholecystectomy is that there is substantial morbidity and mortality associated with emergent biliary operations in transplant patients. Graham et al4 reported morbidity in 14% and mortality in 7% of renal and pancreas transplant patients who required emergent biliary tract interventions as well as a 20% graft loss. The Mayo Clinic experience documented a mortality rate of 29% in heart and lung transplant patients who required emergent biliary tract surgery in the posttransplantation period.5 An older series reported 4 major complications and 3 eventual mortalities in 7 patients who had emergent cholecystectomies after cardiac transplantation.13 Conversely, 17 patients had elective cholecystectomies (open) with no reported morbidity or mortality. The significant disparity between elective and emergent and morbidity and mortality outcomes have provided the rational for preemptive cholecystectomy for patients with asymptomatic cholelithiasis after transplantation. However, most studies reporting high morbidity and mortality rates have a biliary tract screening of only 10% to 30%; thus, there is a selection bias or there is a significant cohort of transplant patients with asymptomatic cholelithiasis who do not go on to develop complications. There is a relative scarcity of data available regarding the natural history of asymptomatic cholelithiasis in postcardiac transplant patients.
This study identified 43 patients (25.6% of the transplantation population) with radiographic evidence of biliary tract pathology after cardiac transplantation. Most studies were performed for suspicion of biliary tract disease. Roughly half of the patients (21/43) were treated with cholecystectomy, while the remaining patients were followed up expectantly (22/43). Over a mean follow-up period of 3.7 years, none (n = 9) of the patients with asymptomatic cholelithiasis managed conservatively developed biliary tract symptoms or needed an operative intervention on their biliary tree, suggesting that expectant management may be safe and appropriate for this patient population. Furthermore, this series confirms significant morbidity associated with all operative interventions on the biliary tree. Thirty-three percent of patients undergoing cholecystectomy developed significant complications. In contrast to other series, there was no significant increase in postoperative morbidity following emergent procedures compared with elective operations in our series.3,5,14 Major complications incurred following elective cholecystectomy include rupture of pseudocyst on postoperative day 3, recurrent choledocholithiasis, cerebrovascular accident, and acute renal failure requiring hemodialysis. The only major outcomes difference between emergent and elective cholecystectomy was a significant increase in length of stay in the hospital.
Patients with an elevated serum bilirubin level were more likely to have a negative imaging study. Many of these patients were in the intensive care unit. They had biliary tract imaging for an increased serum bilirubin level, which was likely from cholestasis related to perioperative low blood flow to the liver. Venous congestion of the liver is also common in these patients and may be related to the significant numbers of ultrasonograms that were positive for gallbladder wall thickening. We consider gallbladder wall thickening a nonspecific finding in cardiac transplant patients, especially if they have poor graft function or if they are in the immediate postoperative period. In general, biliary tract pathology necessitating an operation did not occur in the immediate posttransplantation hospital course.
Diabetic patients may be an exception to expectant management of asymptomatic cholelithiasis after cardiac transplantation. Diabetic patients have a particularly aggressive course of biliary tract pathology. This series suggests that diabetic patients were more likely to present acutely with abdominal pain and require an emergent operation. Epidemiologic data and experimental series generally support the concept that diabetic persons in the general population have an increased risk of cholelithiasis.15- 17 In the past, prophylactic cholecystectomy was common in diabetic patients with asymptomatic gallstones. More recent literature has noted that many diabetic patients in the general population also remain asymptomatic and prophylactic cholecystectomies are no longer standard practice.14,18 Diabetes mellitus and a heart transplantation are both significant risk factors that may synergistically increase morbidity and mortality following emergent cholecystectomy, suggesting that these patients may benefit from preemptive cholecystectomy.14,19
In summary, this series confirms that the development of postcardiac transplantation biliary tract pathology is common (20.8%), although the absolute risk of requiring an emergent operation is low (4.2%). These data suggest that the morbidity of an elective cholecystectomy in cardiac transplant patients is significant and equivalent to the morbidity associated with emergent procedures. Expectant management of nonacutely ill patients with cholelithiasis discovered after transplantation was safe in this series. Diabetic patients may benefit from preemptive cholecystectomy after cardiac transplant.
This study is limited by its small numbers and retrospective nature. To our knowledge, there are no prospective or randomized prospective trials addressing prophylactic cholecystectomy. The debate will continue until randomized, prospective trials are completed.
Correspondence: Michael J. Englesbe, MD, University of Michigan Health System, 2926 Taubman Center, 1500 E Medical Center Dr, Ann Arbor, MI 48109-0331 (email@example.com).
Accepted for Publication: September 30, 2004.